Transient endothelial injury and release of lupus anticoagulant in COVID-19

Libby P, Lüscher T (2020) COVID-19 is, in the end, an endothelial disease. Eur Heart J 41:3038–3044

Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP et al (2020) Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med 383:288–290

Siguret V, Voicu S, Neuwirth M, Delrue M, Gayat E, Stépanian A et al (2020) Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? Thromb Res 195:74–76

Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N, et al. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 2021

Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346:752–763

Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18:844–847

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM et al (2020) Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 191:148–150

Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, Suarez-Almazor ME (2016) Systematic review of case reports of antiphospholipid syndrome following infection. Lupus 25:1520–1531